In addition to completing development of our pipeline products in post-operative pain, breakthrough pain, and procedural sedation, AcelRx is preparing to introduce these products to patients in the United States, either through its own efforts or, in select cases, in conjunction with a partner.
Outside of the United States, AcelRx anticipates commercializing these products on a worldwide basis through select regional partnerships. We recognize that partnerships, both in the United States and worldwide, are a key part of maximizing the therapeutic and commercial potential of our products. In all our partnerships, our goal is to create a win-win environment that allows the partnership and the product to flourish, thereby ensuring that patients get the care they need. We welcome the opportunity to talk with potential commercialization partners worldwide about licensing relationships, development collaborations, and strategic alliances that complement and extend our own development and commercial capabilities. To discuss potential partnering opportunities, please contact:
President and Chief Executive Officer